New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage
Yin Guo-qing, Jun Li, Bei Zhong, Yong-Fong Yang, Maorong Wang
Abstract
IU/mL is feasible and would provide better prognosis; and (2) Further research is needed to assess the long-term toxic effects of higher entecavir doses (2.5 and 5.0 mg/d), which may prove beneficial in treating patients with prior NA treatment, partial virological response, or LLV state.
Topics & Concepts
EntecavirViremiaMedicineVirologyHepatitis B virusVirusHepatitis a virusImmunologyChronic hepatitisLamivudineHepatitis B Virus StudiesHepatitis C virus researchLiver Disease Diagnosis and Treatment